Clinical Trial Update: Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with anti-PD-1/PD-L1 and pl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• DOCETAXEL (DOCETAXEL)
• cabozantinib (cabozantinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2023-12-20